Pune Magazine

Osteosarcoma Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

 Breaking News
  • No posts were found

Osteosarcoma Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

March 10
06:33 2023
Osteosarcoma Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type

DelveInsight’s, “Osteosarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 30+ Osteosarcoma companies and 30+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including Osteosarcoma clinical trials and nonclinical stage products. Osteosarcoma pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Osteosarcoma Emerging drugs, the Osteosarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Osteosarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Osteosarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Osteosarcoma clinical trials studies, Osteosarcoma NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Osteosarcoma Pipeline Report

 

  • Over 30+ Osteosarcoma companies are evaluating 30+ Osteosarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Osteosarcoma market would significantly increase market revenue.

 

  • The leading Osteosarcoma Companies includes AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd, George Clinical Pty Ltd, Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., Merck & Co, Hutchison Medipharma Limited, MacroGenics, Gradalis, Inc., Shanghai Pharmaceuticals Holding, Celgene, Oncternal Therapeutics, Valent Technologies, and others.

  

  • Promising Osteosarcoma Companies include Lenvatinib, Ifosfamide, Etoposide, Methotrexate, Calcium Folinate, Pemetrexed, Mifamurtide (L-MTP-PE), Cisplatin liposomal, Inhaled Lipid Cisplatin (ILC), Interferon Alpha, and others.

 

  • The Osteosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The Osteosarcoma pipeline therapies under development are focused on novel approaches to treat/improve Osteosarcoma.

 

Request a sample and discover the recent breakthroughs happening in the Osteosarcoma Pipeline landscape @ Osteosarcoma Pipeline Outlook Report

 

Osteosarcoma Overview

A “Sarcoma” is a type of cancer that that develops in connective tissue such as bone, cartilage, or muscle and “Osteo” refers to bones. Osteosarcoma or osteogenic sarcoma is a type of cancer that starts in the bones. Osteosarcoma is a rare type of bone cancer in which malignant (cancerous) cells produce irregular bone. Although osteosarcoma can affect people of all ages, it most often occurs in children and teens who are still growing. The tumor usually develops at the ends of the long bones, specifically around the knee and in the shoulder, but can occur anywhere in the body. The cause is not known. In some cases, osteosarcoma runs in families.

 

Recent Developmental Activities in the Osteosarcoma Treatment Landscape

 

  • ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.

 

For further information, refer to the detailed Osteosarcoma Drugs Launch, Osteosarcoma Developmental Activities, and Osteosarcoma News, click here for Osteosarcoma Ongoing Clinical Trial Analysis

 

Osteosarcoma Emerging Drugs Profile

 

  • ZKAB-001: Lee’s Pharmaceutical

ZKAB001 is a fully human anti-PD-L1 monoclonal antibody targeting tumor PD-L1 protein. It can release the “brake” causing by the tumor cell to the immune system. A phase I clinical trial in osteosarcoma patients who underwent upfront therapy to evaluate whether ZKAB001 can prevent tumor recurrence was completed early this year and the encouraging results therefrom has led to the initiation of this phase III clinical trial titled “Study of ZKAB001 for Maintenance Therapy in Patients with High-grade Osteosarcoma after Adjuvant Chemotherapy”.

 

  • Lenvatinib: Eisai Co Ltd/Merck & Co

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. Currently it is being investigated in Phase II stage of development to provide the potential treatment for the patients with osteosarcoma.

 

  • ZN c3: Zentalis Pharmaceuticals 

ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma. 

 

Osteosarcoma Pipeline Therapeutics Assessment

There are approx. 30+ key Osteosarcoma companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. phase III include, Lee’s Pharmaceutical.

 

Find out more about the Osteosarcoma Pipeline Segmentation, Therapeutics Assessment, and Osteosarcoma Emerging Drugs @ Osteosarcoma Treatment Landscape

 

Scope of the Osteosarcoma Pipeline Report

 

  • Coverage- Global

 

  • Osteosarcoma Companies- AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd, George Clinical Pty Ltd, Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., Merck & Co, Hutchison Medipharma Limited, MacroGenics, Gradalis, Inc., Shanghai Pharmaceuticals Holding, Celgene, Oncternal Therapeutics, Valent Technologies, and others.

 

  • Osteosarcoma Pipeline Therapies- Lenvatinib, Ifosfamide, Etoposide, Methotrexate, Calcium Folinate, Pemetrexed, Mifamurtide (L-MTP-PE), Cisplatin liposomal, Inhaled Lipid Cisplatin (ILC), Interferon Alpha, and others.

 

  • Osteosarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Osteosarcoma Pipeline Companies and Therapies, click here @ Osteosarcoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Osteosarcoma: Overview
  4. Osteosarcoma Pipeline Therapeutics
  5. Osteosarcoma Therapeutic Assessment
  6. Osteosarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ZKAB-001: Lee’s Pharmaceutical
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Lenvatinib: Eisai Co Ltd/Merck & Co
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ZN c3: Zentalis Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Osteosarcoma Key Companies
  18. Osteosarcoma Key Products
  19. Osteosarcoma- Unmet Needs
  20. Osteosarcoma- Market Drivers and Barriers
  21. Osteosarcoma- Future Perspectives and Conclusion
  22. Osteosarcoma Analyst Views
  23. Osteosarcoma Key Companies
  24. Appendix

 

Got Queries? Find out the related information on Osteosarcoma Mergers and acquisitions, Osteosarcoma Licensing Activities @ Osteosarcoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories